Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Inhibikase Therapeutics' NDA for chronic myelogenous leukemia cleared by FDA » 08:03
08/26/22
08/26
08:03
08/26/22
08:03
IKT

Inhibikase Therapeutics

/

+

Inhibikase Therapeutics…

Inhibikase Therapeutics announced that the FDA has reviewed its Investigational New Drug - IND - application for IkT-001Pro for the treatment of Chronic Myelogenous Leukemia - CML - and issued a Study May Procced letter. IkT-001Pro is a prodrug formulation of imatinib mesylate and has been developed to improve the safety of the first FDA-approved Abelson kinase inhibitor, imatinib. Imatinib is commonly taken for hematological and gastrointestinal cancers that arise from Abl kinase mutations found in the bone marrow or for gastrointestinal cancers that occur from c-Kit and/or PDGFRa/b mutations in the stomach; c-Kit, PDGFRa/b and Abl are all members of the Abelson Tyrosine Kinase protein family. Imatinib delivered as IkT-001Pro was granted Orphan Drug Designation for stable-phase CML in September, 2018. The study is designed to evaluate the safety profile of IkT-001Pro as well as identify a dose with a similar systemic exposure and pharmacokinetic profile compared to 400 mg imatinib mesylate at 96 hours post administration.

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
/

+

Hot Stocks
Inhibikase Therapeutics doses first patient in Phase 2a study of IkT-148009 » 08:04
08/23/22
08/23
08:04
08/23/22
08:04
IKT

Inhibikase Therapeutics

/

+

Inhibikase Therapeutics…

Inhibikase Therapeutics announced dosing of the first patient in its Phase 2a study evaluating IkT-148009, the Company's novel Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson's disease. The 201 trial is a 1:1:1:1 randomized, double-blind, twelve-week dosing trial that will measure the safety, tolerability and steady-state pharmacokinetics of IkT-148009 as primary endpoints. The trial will enroll approximately 120 patients with untreated Parkinson's disease who have not yet progressed to the need for symptomatic therapy. Patients will be treated at one of three randomized doses, either 50, 100 or 200 mg given once daily, or to a placebo dose. The trial will also measure a hierarchy of Parkinson's-related disease assessments in the brain and gut as secondary or exploratory endpoints. The 201 trial is currently screening patients across 12 of a planned 40 sites in North America with additional site activations ongoing on a rolling basis.

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
/

+

Over a quarter ago
Hot Stocks
Inhibikase Therapeutics advances IkT-148009 Phase 2 '201' program » 08:14
06/13/22
06/13
08:14
06/13/22
08:14
IKT

Inhibikase Therapeutics

/

+

Inhibikase Therapeutics…

Inhibikase Therapeutics announced that it is advancing its Phase 2a study, '201 trial,' following review of the study protocol and Phase 1/1b data by the U.S. FDA.

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
/

+

07/15/21 JonesTrading
Inhibikase Therapeutics initiated with a Buy at JonesTrading
  • 16
    Jun
Conference/Events
B. Riley to hold a virtual conference » 10:06
04/27/22
04/27
10:06
04/27/22
10:06
SEEL

Seelos Therapeutics

/

+

, HROW

Harrow Health

$6.56 /

+0.22 (+3.47%)

, CGTX

Cognition Therapeutics

$2.83 /

-0.035 (-1.22%)

, FREQ

Frequency Therapeutics

$1.40 /

+0.005 (+0.36%)

, IKT

Inhibikase Therapeutics

$1.11 /

+ (+0.00%)

, MNOV

MediciNova

$2.65 /

-0.095 (-3.46%)

, NGM

NGM Biopharmaceuticals

$14.82 /

+0.21 (+1.44%)

, SRNE

Sorrento Therapeutics

$1.61 /

-0.005 (-0.31%)

, TNXP

Tonix Pharmaceuticals

/

+

Annual Neuro &…

Annual Neuro & Ophthalmology Virtual Investor Conference to be held on April 27.

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
/

+

SRNE Sorrento Therapeutics
$1.61 /

-0.005 (-0.31%)

SEEL Seelos Therapeutics
/

+

NGM NGM Biopharmaceuticals
$14.82 /

+0.21 (+1.44%)

MNOV MediciNova
$2.65 /

-0.095 (-3.46%)

IKT Inhibikase Therapeutics
$1.11 /

+ (+0.00%)

HROW Harrow Health
$6.56 /

+0.22 (+3.47%)

FREQ Frequency Therapeutics
$1.40 /

+0.005 (+0.36%)

CGTX Cognition Therapeutics
$2.83 /

-0.035 (-1.22%)

SEEL Seelos Therapeutics
/

+

03/14/22 B. Riley
Seelos Therapeutics price target lowered to $4 from $6 at B. Riley
03/08/22 Cantor Fitzgerald
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald
01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
HROW Harrow Health
$6.56 /

+0.22 (+3.47%)

10/14/21 B. Riley
Harrow Health resumed with a Buy at B. Riley
10/14/21 B. Riley
Harrow Health resumed with a Buy at B. Riley
10/14/21 B. Riley
Harrow Health resumed with a Buy at B. Riley
09/23/21 Aegis
Harrow Health initiated with a Buy at Aegis
CGTX Cognition Therapeutics
$2.83 /

-0.035 (-1.22%)

04/22/22 Ladenburg
Cognition Therapeutics initiated with a Buy at Ladenburg
01/24/22 B. Riley
Cognition Therapeutics price target lowered to $20 from $27 at B. Riley
11/03/21
Fly Intel: Top five analyst initiations
11/03/21 B. Riley
Cognition Therapeutics initiated with a Buy at B. Riley
FREQ Frequency Therapeutics
$1.40 /

+0.005 (+0.36%)

03/23/22 B. Riley
Frequency Therapeutics price target lowered to $10 from $17 at B. Riley
01/24/22 B. Riley
Frequency Therapeutics price target lowered to $17 from $21 at B. Riley
09/22/21 Goldman Sachs
Frequency Therapeutics downgraded to Neutral from Buy at Goldman Sachs
05/17/21 B. Riley
Frequency Therapeutics price target lowered to $21 from $35 at B. Riley
IKT Inhibikase Therapeutics
$1.11 /

+ (+0.00%)

07/15/21 JonesTrading
Inhibikase Therapeutics initiated with a Buy at JonesTrading
MNOV MediciNova
$2.65 /

-0.095 (-3.46%)

01/24/22 B. Riley
MediciNova price target lowered to $6 from $11 at B. Riley
NGM NGM Biopharmaceuticals
$14.82 /

+0.21 (+1.44%)

03/02/22 Raymond James
NGM Biopharmaceuticals downgraded to Outperform from Strong Buy at Raymond James
01/07/22 Piper Sandler
NGM Biopharmaceuticals price target raised to $32 from $30 at Piper Sandler
09/16/21 BMO Capital
NGM Biopharmaceuticals price target raised to $35 from $29 at BMO Capital
09/12/21 Raymond James
NGM Biopharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
SRNE Sorrento Therapeutics
$1.61 /

-0.005 (-0.31%)

03/25/22 H.C. Wainwright
Sorrento Therapeutics price target lowered to $20 from $26 at H.C. Wainwright
12/28/21 H.C. Wainwright
H.C. Wainwright reiterates $26 target on Sorrento after Covistix news
08/09/21 H.C. Wainwright
Sorrento Therapeutics price target lowered to $26 from $30 at H.C. Wainwright
TNXP Tonix Pharmaceuticals
/

+

04/18/22 Noble Capital
Tonix Pharmaceuticals initiated with an Outperform at Noble Capital
08/31/21 Alliance Global Partners
Alliance Global Partners ups Tonix target to $3 amid NIH interest in Long-COVID
08/11/21 Alliance Global Partners
Tonix Pharmaceuticals price target lowered to $2 from $4 at Alliance Global Partners
TNXP Tonix Pharmaceuticals
/

+

NGM NGM Biopharmaceuticals
$14.82 /

+0.21 (+1.44%)

HROW Harrow Health
$6.56 /

+0.22 (+3.47%)

FREQ Frequency Therapeutics
$1.40 /

+0.005 (+0.36%)

CGTX Cognition Therapeutics
$2.83 /

-0.035 (-1.22%)

  • 08
    Oct
  • 16
    Jun
  • 20
    May
SRNE Sorrento Therapeutics
$1.61 /

-0.005 (-0.31%)

HROW Harrow Health
$6.56 /

+0.22 (+3.47%)

CGTX Cognition Therapeutics
$2.83 /

-0.035 (-1.22%)

SRNE Sorrento Therapeutics
$1.61 /

-0.005 (-0.31%)

SEEL Seelos Therapeutics
/

+

Conference/Events
Inhibikase Therapeutics to hold a virtual KOL investor event » 09:50
04/20/22
04/20
09:50
04/20/22
09:50
IKT

Inhibikase Therapeutics

$1.18 /

+0.04 (+3.51%)

Virtual KOL Investor…

Virtual KOL Investor Event to be held on April 20 at 10 am. Webcast Link

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
$1.18 /

+0.04 (+3.51%)

IKT Inhibikase Therapeutics
$1.18 /

+0.04 (+3.51%)

07/15/21 JonesTrading
Inhibikase Therapeutics initiated with a Buy at JonesTrading
04/26/21 ThinkEquity
Inhibikase Therapeutics initiated with a Buy at ThinkEquity
  • 16
    Jun
Conference/Events
Inhibikase Therapeutics to hold a virtual KOL investor event » 04:55
04/20/22
04/20
04:55
04/20/22
04:55
IKT

Inhibikase Therapeutics

$1.14 /

-0.015 (-1.30%)

Virtual KOL Investor…

Virtual KOL Investor Event to be held on April 20 at 10 am. Webcast Link

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
$1.14 /

-0.015 (-1.30%)

IKT Inhibikase Therapeutics
$1.14 /

-0.015 (-1.30%)

07/15/21 JonesTrading
Inhibikase Therapeutics initiated with a Buy at JonesTrading
04/26/21 ThinkEquity
Inhibikase Therapeutics initiated with a Buy at ThinkEquity
  • 16
    Jun
Conference/Events
Inhibikase Therapeutics to hold a virtual KOL investor event » 00:21
04/18/22
04/18
00:21
04/18/22
00:21
IKT

Inhibikase Therapeutics

$1.27 /

+0.01 (+0.79%)

Virtual KOL Investor…

Virtual KOL Investor Event to be held on April 20 at 10 am. Webcast Link

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
$1.27 /

+0.01 (+0.79%)

IKT Inhibikase Therapeutics
$1.27 /

+0.01 (+0.79%)

07/15/21 JonesTrading
Inhibikase Therapeutics initiated with a Buy at JonesTrading
04/26/21 ThinkEquity
Inhibikase Therapeutics initiated with a Buy at ThinkEquity
  • 16
    Jun
Syndicate
Inhibikase Therapeutics files $100M mixed securities shelf  06:40
02/07/22
02/07
06:40
02/07/22
06:40
IKT

Inhibikase Therapeutics

$1.29 /

-0.095 (-6.86%)

 
ShowHide Related Items >><<
IKT Inhibikase Therapeutics
$1.29 /

-0.095 (-6.86%)

IKT Inhibikase Therapeutics
$1.29 /

-0.095 (-6.86%)

07/15/21 JonesTrading
Inhibikase Therapeutics initiated with a Buy at JonesTrading
04/26/21 ThinkEquity
Inhibikase Therapeutics initiated with a Buy at ThinkEquity
  • 16
    Jun
Hot Stocks
Inhibikase Therapeutics announces publication on c-Abl » 08:22
11/29/21
11/29
08:22
11/29/21
08:22
IKT

Inhibikase Therapeutics

$2.05 /

+0.03 (+1.49%)

Inhibikase Therapeutics…

Inhibikase Therapeutics announced the publication of a paper describing the biochemical rationale and potential benefit of Abelson Tyrosine Kinase, c-Abl, inhibition as a potential disease-modifying therapy for Parkinson's Disease. The article, titled "Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity" was published online in the journal Movement Disorders on November 24, 2021. The publication analyzes the role of both c-Abl, a non-receptor tyrosine kinase, as well as misfolded alpha-synuclein in the initiation and progression of Parkinson's disease, PD. Therapeutic administration of IkT-148009, a highly selective c-Abl kinase inhibitor, demonstrated the ability to clear alpha-synuclein aggregates from the brain and GI tract, promote regeneration of neurons, and induce substantial functional recovery in measures of motor and non-motor function. These studies support that the inhibition of c-Abl could have disease modifying effects and further support the continued clinical development of IkT-148009. "Parkinson's disease affects an estimated one million people in the U.S. and remains a significant unmet medical need. Today's publication provides a detailed mechanistic understanding of the early steps in the disease process and the role c-Abl plays in neurodegeneration. Our lead candidate, IkT-148009, a selective c-Abl kinase inhibitor, has demonstrated the potential to halt and reverse disease progression in animal models," stated Milton H. Werner, Ph.D., President and Chief Executive Officer of Inhibikase Therapeutics and principal author of the manuscript published today along with co-author and Interim Chief Medical Officer Dr. Warren Olanow. "IkT-148009 is currently in a Phase 1b extension study in Parkinson's patients, which we believe will give us an early look into safety and tolerability of IkT-148009 in patients and evaluate potential improvements across motor and non-motor aspects of the disease in patients over 7-day dosing. We anticipate completing this extension study in 2022, and expect to present data from our Phase 1 and possibly Phase 1b studies at the AD-PD Meeting to be held March 15-20, 2022 in Barcelona, Spain."

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
$2.05 /

+0.03 (+1.49%)

IKT Inhibikase Therapeutics
$2.05 /

+0.03 (+1.49%)

07/15/21 JonesTrading
Inhibikase Therapeutics initiated with a Buy at JonesTrading
04/26/21 ThinkEquity
Inhibikase Therapeutics initiated with a Buy at ThinkEquity
  • 16
    Jun
IKT Inhibikase Therapeutics
$2.05 /

+0.03 (+1.49%)

Hot Stocks
Inhibikase doses first Parkinson's patient in clinical trial of IkT-148009 » 08:10
10/19/21
10/19
08:10
10/19/21
08:10
IKT

Inhibikase Therapeutics

$1.76 /

-0.165 (-8.59%)

Inhibikase Therapeutics…

Inhibikase Therapeutics announced dosing of the first Parkinson's patient in its Phase 1b clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson's disease. The Phase 1b extension study is a 3:1 randomized, placebo-controlled trial investigating the safety, tolerability and pharmacokinetics of IkT-148009. The trial will enroll a total of 24 patients with Parkinson's disease across 3 escalating doses (8 patients per cohort). The study will also assess cognitive, motor function, gut motility and measures of alpha-synuclein aggregate clearance in multiple compartments, as exploratory endpoints. The Company previously reported results from its Phase 1 study of IkT-148009 in older and elderly healthy volunteers, which achieved high drug exposure between 12.5 and 100 mg with no clinically significant adverse events across 56 patients. These results were consistent with exposures observed in animal efficacy studies of inherited and sporadic progressive Parkinson's disease.

ShowHide Related Items >><<
IKT Inhibikase Therapeutics
$1.76 /

-0.165 (-8.59%)

IKT Inhibikase Therapeutics
$1.76 /

-0.165 (-8.59%)

07/15/21 JonesTrading
Inhibikase Therapeutics initiated with a Buy at JonesTrading
04/26/21 ThinkEquity
Inhibikase Therapeutics initiated with a Buy at ThinkEquity
  • 16
    Jun
  • 28
    Oct
IKT Inhibikase Therapeutics
$1.76 /

-0.165 (-8.59%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.